Skip to main content
    P

    Phibro Animal Health Corporation (PAHC)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ

    $35.02
    -0.95 (-2.64%)

    Market Cap: $1.46B

    Last updated: Nov 17, 2026 at 11:04 AM ET

    Phibro Animal Health Corporation (PAHC) Earnings: Report Dates and Results

    Updated Nov 4, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Phibro Animal Health (PAHC) is expected to report earnings on Feb 2, 2027. In the quarter ended Sep 30, 2026, Phibro Animal Health reported EPS of $0.79, in line with the $0.79 estimate. It beat the EPS estimate in 7 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    60%(24/40)
    Avg Surprise
    +4.99%

    Upcoming Estimates

    Reports Feb 2, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus$0.94
    Range$0.91 - $0.97
    2 analysts
    EPS Revisions
    1
    0
    30d
    EPS Estimate DriftChange to current
    90d ago$0.91+3.0%
    60d ago$0.97-2.9%
    30d ago$0.99-5.3%
    7d ago$0.94-0.2%
    Current$0.94
    Revenue Consensus
    $402.00M
    Range$402.00M - $402.00M
    1 analysts
    Reports May 4, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus$0.87
    Range$0.84 - $0.89
    2 analysts
    EPS Revisions
    1
    0
    30d
    EPS Estimate DriftChange to current
    90d ago$0.80+8.4%
    60d ago$0.86+0.7%
    30d ago$0.85+2.0%
    7d ago$0.88-1.3%
    Current$0.87
    Revenue Consensus
    $397.00M
    Range$397.00M - $397.00M
    1 analysts

    Next Report

    PAHC has an expected report date of Feb 2, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 8.0% above the $0.87 reported for the quarter ended Dec 31, 2025.

    PAHC Earnings Call

    The latest PAHC earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 40 quarters below that had an estimate, PAHC beat 24, missed 14 and matched 2. Revenue for the quarter ended Sep 30, 2026 was $386.77M, up 6.3% from $363.89M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026$0.79$0.79$0.76 - $0.810.00%In line+8.2%30 up, 1 downNov 4, 2026$386.77M
    Jun 30, 2026$0.85$0.72$0.68 - $0.75+18.06%Beat+49.1%40 up, 1 downAug 26, 2026$396.75M
    Mar 31, 2026$0.76$0.71$0.70 - $0.73+7.04%Beat+20.6%52 up, 0 downMay 6, 2026$383.54M
    Dec 31, 2025$0.87$0.67$0.62 - $0.72+29.85%Beat+61.1%41 up, 1 downFeb 4, 2026$373.91M
    Sep 30, 2025$0.73$0.59$0.52 - $0.68+23.73%Beat+108.6%31 up, 0 downNov 5, 2025$363.89M
    Jun 30, 2025$0.57$0.52$0.50 - $0.54+9.62%Beat+39.0%30 up, 3 downAug 27, 2025$378.70M
    Mar 31, 2025$0.63$0.52$0.49 - $0.56+21.15%Beat+103.2%30 up, 2 downMay 7, 2025$347.82M
    Dec 31, 2024$0.54$0.45$0.40 - $0.48+20.00%Beat+63.6%31 up, 1 downFeb 5, 2025$309.26M
    Sep 30, 2024$0.35$0.25$0.20 - $0.30+40.00%Beat+150.0%41 up, 0 downNov 7, 2024$260.43M
    Jun 30, 2024$0.41$0.33$0.33 - $0.34+24.24%Beat+7.9%30 up, 0 downAug 28, 2024$273.16M
    Mar 31, 2024$0.31$0.29$0.29 - $0.29+6.90%Beat+6.9%30 up, 0 downMay 8, 2024$263.22M
    Dec 31, 2023$0.33$0.28$0.24 - $0.32+17.86%Beat-2.9%40 up, 0 downFeb 7, 2024$249.94M
    Sep 30, 2023$0.14$0.23$0.20 - $0.28-39.13%Miss-33.3%30 up, 0 downNov 8, 2023$231.35M
    Jun 30, 2023$0.38$0.38$0.37 - $0.420.00%In line+5.6%40 up, 0 downAug 30, 2023$255.05M
    Mar 31, 2023$0.29$0.34$0.31 - $0.35-14.71%Miss-12.1%40 up, 0 downMay 3, 2023$245.67M
    Dec 31, 2022$0.34$0.30$0.24 - $0.35+13.33%Beat-8.1%40 up, 0 downFeb 8, 2023$244.65M
    Sep 30, 2022$0.21$0.27$0.24 - $0.30-22.22%Miss-16.0%30 up, 0 downNov 9, 2022$232.52M
    Jun 30, 2022$0.36$0.38$0.35 - $0.42-5.26%Miss+12.5%31 up, 0 downAug 24, 2022$255.26M
    Mar 31, 2022$0.33$0.35$0.34 - $0.36-5.71%Miss-2.9%30 up, 0 downMay 4, 2022$239.62M
    Dec 31, 2021$0.37$0.33$0.32 - $0.34+12.12%Beat+8.8%30 up, 0 downFeb 9, 2022$232.71M
    Sep 30, 2021$0.25$0.29$0.25 - $0.35-13.79%Miss-7.4%3N/ANov 2, 2021$214.66M
    Jun 30, 2021$0.32$0.31$0.30 - $0.32+3.23%Beat+88.2%4N/AAug 25, 2021$220.28M
    Mar 31, 2021$0.34$0.32$0.32 - $0.39+6.25%Beat-10.5%5N/AMay 6, 2021$211.73M
    Dec 31, 2020$0.34$0.28$0.23 - $0.29+21.43%Beat0.0%5N/AFeb 3, 2021$206.15M
    Sep 30, 2020$0.27$0.23$0.19 - $0.36+17.39%Beat+42.1%5N/ANov 4, 2020$195.19M
    Jun 30, 2020$0.17$0.22$0.15 - $0.28-22.73%Miss-48.5%5N/AAug 26, 2020$185.88M
    Mar 31, 2020$0.38$0.34$0.30 - $0.38+11.76%Beat-2.6%5N/AMay 7, 2020$210.74M
    Dec 31, 2019$0.34$0.29$0.27 - $0.30+17.24%Beat-17.1%5N/AFeb 3, 2020$214.01M
    Sep 30, 2019$0.19$0.24$0.19 - $0.28-20.83%Miss-51.3%5N/ANov 4, 2019$189.72M
    Jun 30, 2019$0.33$0.36$0.33 - $0.42-8.33%Miss-28.3%5N/AAug 27, 2019$203.88M
    Mar 31, 2019$0.39$0.43$0.43 - $0.43-9.30%Miss-18.7%3N/AMay 6, 2019$205.74M
    Dec 31, 2018$0.41$0.43$0.42 - $0.44-4.65%Miss+17.1%3N/AFeb 6, 2019$218.22M
    Sep 30, 2018$0.39$0.41$0.38 - $0.44-4.88%Miss+2.6%3N/ANov 6, 2018$200.15M
    Jun 30, 2018$0.46$0.42$0.37 - $0.44+9.52%Beat+17.9%4N/AAug 27, 2018$211.79M
    Mar 31, 2018$0.48$0.44$0.43 - $0.44+9.09%Beat+14.3%3N/AMay 7, 2018$208.91M
    Dec 31, 2017$0.35$0.39$0.35 - $0.41-10.26%Miss+2.9%5N/AFeb 5, 2018$205.88M
    Sep 30, 2017$0.38$0.37$0.36 - $0.39+2.70%Beat+5.6%5N/ANov 6, 2017$193.41M
    Jun 30, 2017$0.39$0.33$0.33 - $0.33+18.18%Beat-2.5%4N/AAug 30, 2017$194.84M
    Mar 31, 2017$0.42$0.34N/A+23.53%Beat+10.5%N/AN/AMay 8, 2017$189.86M
    Dec 31, 2016$0.34$0.35N/A-2.86%Miss-12.8%N/AN/AFeb 6, 2017$191.60M
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Jun 30, 2026 was $3.21, up 53.6% from the year before. It was $1.51 for the year ended Jun 30, 2017, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Jun 30, 2026$3.21+53.6%
    Jun 30, 2025$2.09+75.6%
    Jun 30, 2024$1.19N/A
    Jun 30, 2023$1.22-6.9%
    Jun 30, 2022$1.31N/A
    Jun 30, 2021$1.27+17.6%
    Jun 30, 2020$1.08-28.9%
    Jun 30, 2019$1.52-9.0%
    Jun 30, 2018$1.67+10.6%
    Jun 30, 2017$1.51N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 2,700 words across 6 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20262,7426
    2026Q2Jun 30, 20263,9479
    2026Q1Mar 31, 20263,1669
    2025Q4Dec 31, 20254,1759
    2025Q3Sep 30, 20253,3276
    2025Q2Jun 30, 20253,8888
    2025Q1Mar 31, 20253,6179
    2024Q4Dec 31, 20243,1556

    2026Q3 Earnings Call

    Opening remarks

    Regina Conference Operator Hello, and thank you for standing by. My name is Regina, and I will be your conference operator today. At this time, I would like to welcome everyone to the Phibro Animal Health Corporation Third Quarter 2026 Earnings Conference Call. I will now turn the conference over to Glenn David, Chief Financial Officer. Please go ahead.

    Glenn David Chief Financial Officer Thank you, Regina. Good day, and welcome to the Phibro Animal Health Corporation Earnings Call for our fiscal third quarter ended March 31, 2026. My name is Glenn David, and I'm the Chief Financial Officer of Phibro Animal Health Corporation. I am joined on today's call by Jack Bendheim, Phibro's Chairman, President and Chief Executive Officer; Daniel Bendheim, Director and Executive Vice President of Corporate Strategy and, as previously announced, our CEO designate; and Larry Miller, Chief Operating Officer. Today, we will cover financial performance for our third quarter and provide updated financial guidance for our fiscal year ending June 30, 2026. At the conclusion of our remarks, we will open the lines for your questions. I would like to remind you that we are providing a simultaneous webcast of this call on our website, pahc.com. Also, on the Investors section of our website, you will find copies of the earnings press release and quarterly Form 10-Q as well as the transcript and slides discussed and presented on this call. Our remarks today will include forward-looking statements, and actual results could differ materially from those projections. For a list and description of certain factors that could cause results to differ, I refer you to the forward-looking statements section in our earnings press release. Our remarks include references to certain financial measures, which were not prepared in accordance with generally accepted accounting principles or U.S. GAAP. I refer you to the non-GAAP financial information section in our earnings press release for a discussion of these measures. Reconciliations of these non-GAAP financial measures to the most directly comparable U.S. GAAP measures are included in the financial tables that accompany the earnings press release. We present our results on a GAAP basis and on an adjusted basis. Our adjusted results exclude acquisition-related items, unusual, nonoperational or nonrecurring items, including stock-based compensation. Other income expense is separately reported in the consolidated statement of operations, including foreign currency losses, gains and income taxes related to pretax income adjustments and unusual or nonrecurring income tax items. Now let me introduce our Chairman, President and Chief Executive Officer, Jack Bendheim, to share his opening remarks. Jack?

    Jack Bendheim Chairman, President and Chief Executive Officer Thanks, Glenn, and good morning, everyone. We had a strong third quarter. Net sales increased 10% to $383 million and adjusted EBITDA increased 11% to $60 million.

    Frequently Asked Questions About PAHC

    When is Phibro Animal Health's next earnings date?

    Phibro Animal Health's next earnings report is expected for Feb 2, 2027.

    Did PAHC beat earnings estimates last quarter?

    Phibro Animal Health reported EPS of $0.79 for the quarter ended Sep 30, 2026, in line with the $0.79 estimate.

    What EPS do analysts expect from PAHC next quarter?

    The consensus EPS estimate for Phibro Animal Health for the quarter ending Dec 31, 2026 is $0.94 from 2 analysts, with estimates from $0.91 to $0.97.

    How often does PAHC beat earnings estimates?

    Phibro Animal Health beat the EPS estimate in 7 of the last 8 quarters, with an average surprise of +16.18%.